James Michael Millis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James Michael Millis has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Witkowski
Department of Surgery, University of Chicago , Chicago, IL
4 shared publications - Adam Krzystyniak
Nencki Institute of Experimental Biology, Warsaw, Poland
2 shared publications Adil Mohamed
Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL 60637, USA
2 shared publicationsAshley Suah
University of Chicago Medicine
2 shared publications- Bryan C. Dickinson
University of Chicago
2 shared publications David C. Cronin
Department of Surgery, Centura Health Physician Group, Denver, CO
2 shared publications
Latest Publications
- 13 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study
Objective: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Summary Background Data: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. Methods: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Results: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P P P P P <0.001) relative to liver-only recurrence. Conclusions: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
- 13 November 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Primary Tumor Biology, Recurrence and Survival After Colorectal Liver Metastasis Resection: The BIO-CRLM Study
Objective: To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Summary Background Data: Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. Methods: An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Results: Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P P P P P <0.001) relative to liver-only recurrence. Conclusions: Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
- Open Access
Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions
In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma. TIL therapy is a form of cell‐based immunotherapy that uses autologous T cells isolated from the tumor microenvironment, which are expanded ex vivo and reinfused to mediate tumor regression after lymphodepleting chemotherapy and high‐dose interleukin‐2. Current data demonstrate durable responses in a subset of heavily pretreated patients with advanced melanoma, and early clinical studies suggest activity in other immunogenic solid tumors. In this review, the historical development of TIL therapy, its current clinical applications, emerging strategies to optimize product composition and the tumor microenvironment, and the critical role of surgeons in TIL procurement and delivery are summarized.
Open AccessTumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions
In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma. TIL therapy is a form of cell‐based immunotherapy that uses autologous T cells isolated from the tumor microenvironment, which are expanded ex vivo and reinfused to mediate tumor regression after lymphodepleting chemotherapy and high‐dose interleukin‐2. Current data demonstrate durable responses in a subset of heavily pretreated patients with advanced melanoma, and early clinical studies suggest activity in other immunogenic solid tumors. In this review, the historical development of TIL therapy, its current clinical applications, emerging strategies to optimize product composition and the tumor microenvironment, and the critical role of surgeons in TIL procurement and delivery are summarized.
- 26 September 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 17-23
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases
- 26 September 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 17-23
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases
- Open Access
- 23 August 2022
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (1) , 66-72
Review Paper on Penetrating Brain Injury
Objective: The aim of this review was to review the ethical and multidisciplinary clinical challenges facing trauma surgeons when resuscitating patients presenting with penetrating brain injury (PBI) and multicavitary trauma. Background: While there is a significant gap in the literature on managing PBI in patients presenting with multisystem trauma, recent data demonstrate that resuscitation and prognostic features for such patients remains poorly described, with trauma guidelines out of date in this field. Methods: We reviewed a combination of recent multidisciplinary evidence-informed guidelines for PBI and coupled this with expert opinion from trauma, neurosurgery, neurocritical care, pediatric and transplant surgery, surgical ethics and importantly our community partners. Results: Traditional prognostic signs utilized in traumatic brain injury may not be applicable to PBI with a multidisciplinary team approach suggested on a case-by-case basis. Even with no role for neurosurgical intervention, neurocritical care, and neurointerventional support may be warranted, in parallel to multicavitary operative intervention. Special considerations should be afforded for pediatric PBI. Ethical considerations center on providing the patient with the best chance of survival. Consideration of organ donation should be considered as part of the continuum of patient, proxy and family-centric support and care. Community input is crucial in guiding decision making or protocol establishment on an institutional level. Conclusions: Support of the patient after multicavitary PBI can be complex and is best addressed in a multidisciplinary fashion with extensive community involvement.
- 23 August 2022
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (1) , 66-72
Open AccessReview Paper on Penetrating Brain Injury
Objective: The aim of this review was to review the ethical and multidisciplinary clinical challenges facing trauma surgeons when resuscitating patients presenting with penetrating brain injury (PBI) and multicavitary trauma. Background: While there is a significant gap in the literature on managing PBI in patients presenting with multisystem trauma, recent data demonstrate that resuscitation and prognostic features for such patients remains poorly described, with trauma guidelines out of date in this field. Methods: We reviewed a combination of recent multidisciplinary evidence-informed guidelines for PBI and coupled this with expert opinion from trauma, neurosurgery, neurocritical care, pediatric and transplant surgery, surgical ethics and importantly our community partners. Results: Traditional prognostic signs utilized in traumatic brain injury may not be applicable to PBI with a multidisciplinary team approach suggested on a case-by-case basis. Even with no role for neurosurgical intervention, neurocritical care, and neurointerventional support may be warranted, in parallel to multicavitary operative intervention. Special considerations should be afforded for pediatric PBI. Ethical considerations center on providing the patient with the best chance of survival. Consideration of organ donation should be considered as part of the continuum of patient, proxy and family-centric support and care. Community input is crucial in guiding decision making or protocol establishment on an institutional level. Conclusions: Support of the patient after multicavitary PBI can be complex and is best addressed in a multidisciplinary fashion with extensive community involvement.
- Top Cited PapersOpen Access
- 25 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (8) , eabi6110
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.
- 25 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (8) , eabi6110
Top Cited PapersOpen AccessCannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.
- 1 January 2022
- Published by Springer Nature
- p. 605-614
Ethics and National Health Policy Change: A Case Study of the Transplant System in China
- 1 January 2022
- Published by Springer Nature
- p. 605-614
Ethics and National Health Policy Change: A Case Study of the Transplant System in China
- Open Access
Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.
Open AccessCannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD), a compound produced by the cannabis plant, inhibits SARS-CoV-2 infection. CBD and its metabolite, 7-OH-CBD, but not congeneric cannabinoids, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after cellular infection, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD induces interferon expression and up-regulates its antiviral signaling pathway. A cohort of human patients previously taking CBD had significantly lower SARS-CoV-2 infection incidence of up to an order of magnitude relative to matched pairs or the general population. This study highlights CBD, and its active metabolite, 7-OH-CBD, as potential preventative agents and therapeutic treatments for SARS-CoV-2 at early stages of infection.